Titers of IgA antibodies against RBD were statistically significantly higher in COVID-19-positive participants with moderate-severe symptoms (mean(SE) = 0.93 ± 0.19) when compared to participants with mild-moderate symptoms (mean(SE) = 0.45 ± 0.05) and asymptomatic participants (mean(SE) = 0.41 ± 0.10) (F(2,25) = 5.73, p = 0.01, Fig. 1a). The gene discussed is CD79A; the disease is COVID-19.